BioCentury
ARTICLE | Clinical News

Qnasl beclomethasone dipropionate nasal aerosol regulatory update

June 2, 2014 7:00 AM UTC

Teva said FDA accepted for review an sNDA for Qnasl beclomethasone dipropionate nasal aerosol to treat seasonal and perennial allergic rhinitis in children 4-11 years of age. The nasal aerosol non-aqu...